Skip to content
Evigrade
CriticalAntiretroviral, HIV protease inhibitor×Ergot alkaloid, 5-HT1B/1D and alpha-adrenoceptor agonist

Updated · Methodology

Mechanism

Atazanavir is both a substrate and an inhibitor of the liver enzyme CYP3A4, so it can raise the levels of other drugs that this enzyme metabolises (atazanavir summary of product characteristics, SmPC, European Medicines Agency, EMA; atazanavir label, US Food and Drug Administration, FDA). In Spain, atazanavir is taken with low-dose ritonavir or in a single tablet with cobicistat, and ritonavir inhibits CYP3A4 more strongly than atazanavir itself (atazanavir and atazanavir/cobicistat SmPCs, EMA). CYP3A4 inhibition raises dihydroergotamine blood levels and the risk of vasospasm with ischaemia of the brain and limbs. With the strong inhibitor itraconazole, exposure to dihydroergotamine itself rose by 14–19%, while exposure to its active metabolite, an equally potent venoconstrictor, rose about 3- to 4-fold (dihydroergotamine labels, FDA). The US atazanavir label links the combination to serious or life-threatening events such as acute ergot toxicity with peripheral vasospasm and ischaemia of the limbs and other tissues (atazanavir label, FDA).

Symptoms

With excess dihydroergotamine, the muscles ache, the fingers and toes become numb, cold, pale or bluish, and pulses in the arms and legs weaken or disappear (dihydroergotamine labels, US Food and Drug Administration, FDA). Leg ischaemia causes cramping and pain in the legs or hips, heaviness or tightness in the leg muscles, burning or aching pain in the feet or toes at rest, and coldness or colour change in one or both legs. Brain ischaemia causes slurred speech and sudden weakness (dihydroergotamine labels, FDA). Myocardial and colonic ischaemia have also been reported. Severe poisoning causes nausea, vomiting, abdominal pain, respiratory depression, a rise and then usually a fall in blood pressure, confusion, delirium, seizures and coma (dihydroergotamine labels, FDA). Persistent vasospasm in people with poor circulation can lead to gangrene or death (dihydroergotamine labels, FDA).

Management

The combination is contraindicated. The EU atazanavir summary of product characteristics (SmPC) contraindicates CYP3A4 substrates with a narrow therapeutic margin and names ergot alkaloids among them, especially ergotamine and dihydroergotamine. The atazanavir/cobicistat SmPC contraindicates dihydroergotamine by name (atazanavir and atazanavir/cobicistat SmPCs, European Medicines Agency, EMA). The US atazanavir label lists dihydroergotamine in its table of contraindicated drugs, with or without ritonavir (atazanavir label, US Food and Drug Administration, FDA). The dihydroergotamine labels, for their part, contraindicate strong CYP3A4 inhibitors and give human immunodeficiency virus (HIV) protease inhibitors, such as ritonavir, as examples (dihydroergotamine labels, FDA). Dihydroergotamine is not in the Spanish medicines register. Before and during treatment with atazanavir plus ritonavir, consider possible interactions and monitor for adverse reactions to the patient's other medicines (atazanavir label, FDA). Tell the patient to stop dihydroergotamine and get emergency help at once if they develop cramping and pain in the legs, numbness, coldness or colour change in the legs, slurred speech or sudden weakness (dihydroergotamine labels, FDA). In overdose, stop dihydroergotamine, support and monitor vital functions, and observe the patient for at least 24 hours or for as long as symptoms persist. Warm the affected area, give vasodilators and provide nursing care to prevent tissue damage (dihydroergotamine labels, FDA).

Your whole list in one report

Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email

Add more drugs

Medicine list: everything you take in one place →

Sources

Other interactions with Atazanavir

Other interactions with Dihydroergotamine